Loading clinical trials...
Loading clinical trials...
A Phase 1, Multicenter, Open-label Study of IBI3020 Treatment in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Conditions
Interventions
IBI3020
Locations
9
United States
Mayo Clinic - Arizona
Pheonix, Arizona, United States
Mayo Clinic - Florida
Jacksonville, Florida, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Montefiore Cancer Center
New York, New York, United States
NEXT Houston
Houston, Texas, United States
NEXT Dallas
Irving, Texas, United States
Start Date
April 29, 2025
Primary Completion Date
December 31, 2027
Completion Date
March 31, 2028
Last Updated
June 6, 2025
NCT06898450
NCT06658951
NCT05719558
NCT05101070
NCT06716138
NCT06307795
Lead Sponsor
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions